Napo Pharmaceuticals
Crofelemer
A proprietary gastro-intestinal compound in clinical development for four distinct product indications
crofelemer
CRO-IBS Indication: Diarrhea-Predominant -IBS (D-IBS), worldwide market
The FDA granted fast-track status to CRO-IBS in December, 2004.